Imagine you’re helping a client who just bought a pair of over-the-counter hearing aids — devices sold without a prescription or an audiologist’s fitting, a category that became federally legal in the US in October 2022 — and two weeks later they’re back, telling you the aids squeal every time they lean in close to someone, and they’ve gone back to just asking people to repeat themselves. Was this a bad product, a bad fit for their hearing profile, or a bad category match entirely? That’s the question this article is built to answer. Since the FDA opened the OTC market, a flood of devices has landed at every price point, and the aggregate review record now contains signal that’s genuinely useful for anyone advising clients or family members navigating this space. The complaint clusters are consistent enough across brands that they function less like random dissatisfaction and more like a diagnostic tool — if you know what to look for, you can pre-screen clients for risk before they spend money they can’t easily recover.
What follows is a pattern-level analysis of the most instructive negative reviews across the OTC category, plus a few cases where “negative” reviews accidentally revealed something useful.
The Three Complaint Clusters That Predict Abandonment
Across aggregated owner reviews compiled through early 2026, three failure modes appear with enough consistency to be treated as structural category risks rather than individual product defects.
Feedback squealing on insertion or at close range. This is the single most common complaint. Owners describe a high-pitched whistle or squeal that triggers when the device isn’t seated correctly in the ear canal, when something comes close to the microphone — a phone handset, a hug, a pillow — or simply when the user reaches up to touch their ear. The FDA’s guidance document “Over-the-Counter Hearing Aids: What You Need to Know” notes that feedback is a known consequence of open-fit designs, the most common OTC form factor, where amplified sound leaks back to the microphone. Without a custom ear mold or a fitted audiologist visit to calibrate the feedback suppression algorithm, the device is working against basic acoustics. Consumer Reports’ 2025 OTC hearing aid follow-up, titled “OTC Hearing Aids: Six Months Later,” found that feedback was cited in a disproportionate share of one- and two-star reviews across multiple brands, and that it correlated strongly with device abandonment within the first 30 days.
Static noise severe enough to cause refusal. Owner review records include accounts of family members sitting next to a parent wearing OTC aids and being able to audibly hear painful static coming from the device. The parent, with no audiologist to consult and no calibration support, refused to wear the devices again. This case is worth dwelling on: the first-time OTC buyer has no professional backstop. When a prescription-dispensed hearing aid produces intolerable output, the audiologist adjusts the gain curve. When an OTC device does it, the owner is alone with a return window and a support phone line. The Hearing Loss Association of America’s OTC Hearing Aid Consumer Guide, 2024 edition, notes that static and distortion complaints spike in devices that apply uniform amplification across frequencies rather than fitting to the individual’s audiogram — a limitation the OTC model accepts by design for mild-to-moderate loss, but which creates real risk when a buyer’s loss profile is more complex than the device assumes.
Post-purchase support that fails disabled users specifically. This is the least-discussed failure mode and arguably the most consequential. Reports from owners of certain budget-tier OTC devices describe being asked, when contacting customer support about a defective unit, to produce a video demonstration of the problem — a requirement that one reviewer described as physically impossible given their disability. That is not a bureaucratic inconvenience; it is a support design that actively excludes the population the device is marketed to. For practitioners advising clients with motor limitations, cognitive fatigue, or limited support systems, this is a genuine pre-purchase risk factor. A device’s support pathway is part of its clinical viability, and documented cases in the review record illustrate why you should ask “what does the support process require of the user?” before recommending any brand.
The Lexie B3 Situation: A Buyer-Protection Issue That Stands Alone
The Lexie B3 occupied a legitimate mid-tier position in the OTC market — Bluetooth connectivity, app-based self-fitting, competent amplification for mild-to-moderate high-frequency loss. Reviewer accounts written mid-ownership note that the company announced the closure of its US operations with no firm warranty commitments for existing device owners.
This deserves explicit framing for anyone still holding stock of these units or advising clients who own them: if the app that powers self-fitting becomes unsupported, the device’s core value proposition degrades. Unlike a basic analog amplifier, which continues to function as hardware regardless of company status, an app-dependent hearing aid becomes progressively less useful as operating system updates break compatibility. The American Speech-Language-Hearing Association’s “OTC Hearing Aid FAQ for Clinicians,” 2024, flags software dependency as an underappreciated long-term risk in the OTC category — a risk that the Lexie situation converted from hypothetical to documented.
If you have a client currently using the Lexie B3: Document what they have now, confirm the current app version works on their phone, and begin identifying alternatives. Do not recommend the Lexie B3 to new buyers until warranty and software continuity commitments are publicly clarified.
When a Situational Amplifier Outperforms a Hearing Aid for a Specific Task
One of the most instructive comparisons in the OTC-adjacent space involves the Williams Sound Pocketalker — a personal sound amplification product, or PSAP, meaning it is not classified as a hearing aid but amplifies sound for situational use, retailing in the $150–$200 range.
MagniPros
$21.80
In stock on Amazon
Check price on AmazonOwner review accounts include reports from individuals who also own premium prescription hearing aids in the $3,000–$4,000 range and wear them daily. Their finding: in the specific context of home TV listening, the Pocketalker produces less distortion than their prescription devices. This is not a takedown of premium hearing aid engineering. It is a reminder that sophisticated prescription aids are optimized for complex acoustic environments — restaurants, conversations in noise, dynamic soundscapes — and that a simple, direct-amplification device with a wired connection to a TV or speaker system sometimes wins on signal clarity for a controlled single-source task.
The Williams Sound Pocketalker is not a hearing aid and should not be recommended as a substitute for one. But for clients whose primary complaint is TV volume at home, and who already wear prescription aids that they find fatiguing after a full day, the Pocketalker’s review record suggests it is a legitimate supplemental option rather than a budget compromise.
By the Numbers
| Scenario | Recommended path | Approximate cost range |
|---|---|---|
| Mild–moderate high-freq loss, first-time buyer, tech-comfortable | OTC hearing aid, self-fitting app | $300–$1,600 |
| Same profile + caregiver support concerns | Consider audiologist-dispensed entry-level | $1,000–$2,500 fitted |
| TV-specific amplification, existing prescription aid user | Personal sound amplifier as supplement | $150–$200 |
| Any buyer where support access is a motor/cognitive concern | Avoid app-dependent OTC; prioritize brands with phone-first support | Varies |
Decision Framework: When to Redirect Away from OTC Entirely
The OTC category is appropriate — and the FDA’s regulatory framework agrees — for adults with perceived mild-to-moderate hearing loss. That is the intended threshold. But the review record reveals several client profiles where OTC is a predictable bad match regardless of budget.
Low-frequency loss predominates. OTC devices are overwhelmingly optimized for high-frequency amplification because age-related hearing loss (presbycusis) typically begins in the high-frequency range. Clients whose loss is primarily in the low frequencies — a pattern seen in some forms of Meniere’s disease, noise-induced loss at certain frequencies, and some congenital loss profiles — are likely to find OTC amplification unhelpful or actively distorting. Wirecutter’s 2025 OTC hearing aid update notes that most OTC devices apply preset gain curves that boost the 2kHz–4kHz range and leave low frequencies comparatively flat. Without an audiogram confirming the loss profile, any device recommendation is an informed guess at best.
No audiologist access and complex loss. The OTC model assumes self-management. For clients who cannot navigate an app, who do not have a support person to assist, or whose loss falls outside the mild-to-moderate range, the absence of a fitting professional is not a feature — it is an exposure.
Support access is restricted by disability. The video-verification support case described above is the clearest example, but it is not unique. Before recommending any OTC device to a client with motor limitations, low vision, or cognitive complexity, verify what the warranty and support process actually requires of the user. “Call us” is a different support model than “send us a video” or “log into the app portal,” and the distinction matters enormously for certain populations. The Hearing Loss Association of America’s OTC Hearing Aid Consumer Guide, 2024 edition, emphasizes that support pathway accessibility is a buyer consideration that receives far less attention than sound quality benchmarks.
Frequently Asked Questions
Why do my new OTC hearing aids squeal, and how do I stop it?
Squealing — technically called feedback — happens when amplified sound leaks out of the ear canal and gets picked up by the device’s microphone, creating a loop. It is most common with open-fit devices, which use a small dome rather than a custom mold, and when the device is not seated fully in the ear. Per the Hearing Loss Association of America’s OTC Hearing Aid Consumer Guide, 2024 edition, first steps are: re-seat the device fully, try a larger dome tip if your kit included one, and reduce the volume. If feedback persists at comfortable volume levels, the device may not be a physical fit for your ear canal shape — a problem an audiologist can solve with a custom mold, but that OTC devices address only imperfectly.
Will an OTC hearing aid help if my hearing loss is mainly in the low frequencies?
Probably not much. Most OTC hearing aids are engineered to amplify high-frequency sounds, which is where the majority of age-related hearing loss occurs. If your loss is primarily in low frequencies, OTC amplification may make speech sound louder without making it clearer — and could introduce distortion. An audiogram from an audiologist or ENT is the only reliable way to know your loss profile before buying. Wirecutter’s 2025 OTC hearing aid update reinforces this point, noting that preset gain curves in most OTC devices are not designed to address atypical loss patterns.
What should I do if the company that made my OTC hearing aids closes or stops supporting the app?
First, check whether the device functions without the app in a basic amplification mode — some do, some do not. Download and save any current app settings or profiles while the app still functions. Contact the company in writing — email, so you have a record — to ask explicitly about warranty obligations and software continuity. If the company is winding down, escalate to your credit card’s dispute process or your state consumer protection office if devices were recently purchased. The Lexie B3 situation is the current benchmark case: owners with active devices are in a genuine gray area, and the absence of clear warranty commitments represents a documented buyer-protection gap in the OTC category.
Is a personal sound amplifier actually better than a cheap hearing aid for home TV use?
For some people, in that specific context, yes — and the comparison is not entirely about price. Personal sound amplifiers such as the Williams Sound Pocketalker use simple wired amplification with direct connection options, which eliminates the Bluetooth latency and digital processing artifacts that can make TV dialogue sound slightly off in OTC hearing aids. The owner accounts comparing the Pocketalker favorably to premium prescription aids for TV listening are making a situational argument, not a global one. A PSAP is not a hearing aid and should not replace one. But as a dedicated TV-listening tool — especially for someone whose primary hearing aid is reserved for conversations and fatiguing environments — it is a credible supplemental choice supported by its owner review record.
How long does it realistically take to adapt to a new OTC hearing aid?
Consumer Reports’ 2025 OTC hearing aid follow-up, “OTC Hearing Aids: Six Months Later,” found that most owners who ultimately rated their devices positively reported a meaningful adjustment period of two to six weeks. The auditory system needs time to recalibrate to amplified input, and new users often find that sounds they have not heard in years — refrigerator hum, ambient traffic, their own voice — feel overwhelming at first. The FDA recommends gradual daily wear increases during the adaptation period. If a device still feels intolerable after six weeks of consistent use, that is a signal to reassess fit, settings, or category appropriateness — not a reason to push through indefinitely.
The OTC hearing aid market has delivered genuine access gains since 2022, and that matters. But the review record is now substantial enough to read as a risk map rather than a collection of individual complaints. Feedback squealing, static-driven abandonment, support processes that exclude disabled users, and company instability are not edge cases — they are patterns. For practitioners advising clients in this category, the pre-purchase checklist now needs to include: What is the client’s loss profile? Can they manage an app independently? What does the support process require of them physically and cognitively? And is the company still operating and honoring warranties? None of those questions appear on a spec sheet, but all of them are legible in the negative review record for anyone who knows where to look.